Top O O O O
news O O O O
from O O O O
across O O O O
the O O O O
health O O O O
care O O O O
landscape. O O O O
Acute O O O O
exacerbation O O O O
of O O O O
interstitial O O O O
lung O O O O
disease O O O O
(AE-ILD) O O O O
is O O O O
a O O O O
less O O O O
frequent O O O O
but O O O O
fatal O O O O
complication O O O O
in O O O O
patients O O O O
with O O O O
idiopathic O O O O
inflammatory O O O O
myopathy O O O O
(IIM); O O O O
however, Reason 4 O O
a Reason 4 O O
regimen Reason 4 O O
of Reason 4 O O
steroids Reason 4 O O
and Reason 4 O O
disease-modifying Reason 4 O O
antirheumatic Reason 4 O O
drugs Reason 4 O O
(DMARDs) Reason 4 O O
was Reason 4 O O
found Reason 4 O O
to Reason 4 O O
reduce Reason 4 O O
short-term Reason 4 O O
death Reason 4 O O
rates, Reason 4 O O
according Reason 4 O O
to Reason 4 O O
[The Reason 4 O O
American Reason 4 O O
Journal Reason 4 O O
of Reason 4 O O
Managed Reason 4 O O
Care](https://www.ajmc.com/newsroom/effects-of-aeild-in-patients-with-idiopathic-inflammatory-myopathy). Reason 4 O O
Investigators O O O O
from O O O O
China O O O O
retrospectively O O O O
observed O O O O
patients O O O O
with O O O O
IIM O O O O
admitted O O O O
to O O O O
a O O O O
hospital O O O O
between O O O O
2007 O O O O
and O O O O
2019 O O O O
to O O O O
understand O O O O
the O O O O
prevalence, O O O O
risk O O O O
factors, O O O O
outcome, O O O O
and O O O O
outcome-related O O O O
factors O O O O
of O O O O
AE-ILD O O O O
in O O O O
patients O O O O
with O O O O
IIM. O O O O
When O O O O
comparing O O O O
the O O O O
64 O O O O
patients O O O O
with O O O O
AE-ILD O O O O
and O O O O
128 O O O O
matched O O O O
patients O O O O
without O O O O
AE-ILD, O O O O
the O O O O
study O O O O
authors O O O O
found O O O O
that O O O O
the O O O O
case O O O O
group O O O O
presented O O O O
with O O O O
significantly O O O O
higher O O O O
on-admission O O O O
disease O O O O
activity O O O O
compared O O O O
with O O O O
the O O O O
controls. O O O O
Monoclonal Reason 4 O O
antibody Reason 4 O O
treatment Reason 4 O O
is Reason 4 O O
able Reason 4 O O
to Reason 4 O O
break Reason 4 O O
apart Reason 4 O O
microbial Reason 4 O O
biofilms, Reason 4 O O
potentially Reason 4 O O
aiding Reason 4 O O
existing Reason 4 O O
antibiotic Reason 4 O O
treatments Reason 4 O O
in Reason 4 O O
more Reason 4 O O
efficiently Reason 4 O O
clearing Reason 4 O O
out Reason 4 O O
infections, Reason 4 O O
according Reason 4 O O
to Reason 4 O O
[Contagion Reason 4 O O
Live](https://www.contagionlive.com/news/new-monoclonal-antibody-treatment-takes-aim-at-bacterial-biofilms). Reason 4 O O
The O O O O
researchers O O O O
tested O O O O
a O O O O
human O O O O
monoclonal O O O O
antibody O O O O
with O O O O
pan-amyloid-binding O O O O
activity, O O O O
mAb O O O O
3H3, O O O O
made O O O O
the O O O O
Samonella O O O O
typhimurium O O O O
biofilms O O O O
less O O O O
tightly O O O O
adherent, O O O O
potentially O O O O
exposing O O O O
the O O O O
eradication O O O O
by O O O O
antibiotics O O O O
that O O O O
work O O O O
in O O O O
tandem O O O O
with O O O O
the O O O O
antibody O O O O
for O O O O
efficacy O O O O
that O O O O
might O O O O
not O O O O
otherwise O O O O
be O O O O
possible. O O O O
In Reason 5 O O
a Reason 5 O O
comparison Reason 5 O O
between Reason 5 O O
standard- Reason 5 O O
and Reason 5 O O
high-dose Reason 5 O O
influenza Reason 5 O O
vaccines, Reason 5 O O
the Reason 5 O O
high-dose Reason 5 O O
vaccine Reason 5 O O
offered Reason 5 O O
greater Reason 5 O O
efficacy Reason 5 O O
for Reason 5 O O
the Reason 5 O O
prevention Reason 5 O O
of Reason 5 O O
influenza Reason 5 O O
hospitalization Reason 5 O O
among Reason 5 O O
adults Reason 5 O O
aged Reason 5 O O
>65 Reason 5 O O
years Reason 5 O O
old, Reason 5 O O
according Reason 5 O O
to Reason 5 O O
[HCP Reason 5 O O
Live](https://www.mdmag.com/medical-news/high-dose-flu-vaccine-more-effective-than-standard-dose). Reason 5 O O
The O O O O
research O O O O
team O O O O
enrolled O O O O
hospitalized O O O O
patients O O O O
with O O O O
acute O O O O
respiratory O O O O
illness O O O O
to O O O O
evaluate O O O O
the O O O O
efficacy O O O O
of O O O O
high-dose O O O O
inactivated O O O O
influenza O O O O
vaccine O O O O
(HD-IIV) O O O O
and O O O O
standard-dose O O O O
influenza O O O O
vaccine O O O O
(SD-IIV) O O O O
for O O O O
prevention O O O O
of O O O O
influenza-associated O O O O
hospitalizations. O O O O
Additional O O O O
evaluation O O O O
of O O O O
HD-IIV O O O O
could O O O O
help O O O O
investigators O O O O
better O O O O
understand O O O O
differences O O O O
in O O O O
relative O O O O
benefit O O O O
of O O O O
the O O O O
vaccine O O O O
across O O O O
studies, O O O O
seasons, O O O O
and O O O O
